TKI monotherapy and TKI plus non-IO therapy was the most common subsequent treatment utilized after receiving IO-TKI. Researchers evaluated survival outcomes, demographic data, and clinical presentation. Past 12 months, the effectiveness and safety between nivolumab plus ipilimumab and pembrolizumab plus axitinib were similar. Researchers compared the efficacy benefits of nivolumab plus cabozantinib with sunitinib alone. The TRAE rates of 1L nivolumab plus ipilimumab were low and remained consistent relative to clinical trials. Researchers evaluated biomarkers to determine their prognostic potential for determining treatment modality for ccRCC. The researchers evaluated the radiographic information of patients with the primary tumor present. Patients with early-onset RCC underwent genetic testing more often than those with bilateral RCC. A Danish study suggests that diabetes has a significant impact on OS in patients with RCC who undergo nephrectomy. A Merit Award-winning abstract offered insight into differences in RCC susceptibility and implications for genetic screening. Zanzalintinib shows promising antitumor activity and manageable toxicity in patients with previously treated advanced ccRCC.